Real-World Retrospective Study of Clinical and Economic Outcomes Among Patients with Locally Advanced or Metastatic Urothelial Carcinoma Treated with First-Line Systemic Anti-Cancer Therapies in the United States: Results from the IMPACT UC-III Study.
Simple Summary: This study evaluated real-world outcomes of first-line treatments for advanced or metastatic bladder cancer in the US from 2020 to 2023, using de-identified health records from 2820 patients. Treatments included chemotherapy (37%), immunotherapy (39%), and other therapies (24%). Soci...
| Publicado en: | Current Oncology Vol. 32; no. 7; pp. 384 - 404 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Jul2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |